铂-话题@MedSci

#铂#

382篇内容 | 6094人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737705, encodeId=e10a1e3770588, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法, objectType=article, longId=213189, objectId=500e213189ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500e213189ee, replyNumber=0, likeNumber=70, createdTime=2022-03-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500e213189ee, moduleTitle=Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500e213189ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737762, encodeId=a1571e377621a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效, objectType=article, longId=293027, objectId=84b729302ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b729302ea0, replyNumber=0, likeNumber=30, createdTime=2022-10-25, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b729302ea0, moduleTitle=Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b729302ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737772, encodeId=02e11e37772c3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, objectType=article, longId=295346, objectId=6f04295346b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f04295346b6, replyNumber=0, likeNumber=71, createdTime=2022-05-31, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f04295346b6, moduleTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f04295346b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737738, encodeId=393a1e37738db, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=72, createdTime=2022-06-20, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737710, encodeId=77c71e3771091, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=70, createdTime=2022-03-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737697, encodeId=16001e3769765, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, objectType=article, longId=211652, objectId=9a1e21165207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1e21165207, replyNumber=0, likeNumber=79, createdTime=2021-11-09, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1e21165207, moduleTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1e21165207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737712, encodeId=0d9c1e37712ab, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, objectType=article, longId=214609, objectId=4c4421460961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c4421460961, replyNumber=0, likeNumber=83, createdTime=2021-12-23, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c4421460961, moduleTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c4421460961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737733, encodeId=e7911e37733c6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Eur J Cancer：采用顺铂或表柔比星进行动脉化疗栓塞治疗肝癌的疗效, objectType=article, longId=218192, objectId=0a32218192bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a32218192bf, replyNumber=0, likeNumber=67, createdTime=2022-08-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a32218192bf, moduleTitle=Eur J Cancer：采用顺铂或表柔比星进行动脉化疗栓塞治疗肝癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a32218192bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737704, encodeId=424a1e37704d6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=212816, objectId=bee72128164e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee72128164e, replyNumber=0, likeNumber=73, createdTime=2021-12-18, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee72128164e, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee72128164e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737718, encodeId=27151e3771851, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Nat Med：Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究, objectType=article, longId=215448, objectId=f2db21544877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2db21544877, replyNumber=0, likeNumber=66, createdTime=2022-06-30, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2db21544877, moduleTitle=Nat Med：Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2db21544877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737703, encodeId=e63c1e3770373, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=67, createdTime=2022-01-07, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737709, encodeId=4c8a1e3770960, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果, objectType=article, longId=213341, objectId=9b0321334101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0321334101, replyNumber=0, likeNumber=71, createdTime=2021-12-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0321334101, moduleTitle=Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b0321334101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737711, encodeId=99401e377112e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Eur Arch Otorhinolaryngol：顺铂化疗对内耳功能和血清prestin浓度的影响 , objectType=article, longId=214397, objectId=df2021439e7e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2021439e7e, replyNumber=0, likeNumber=71, createdTime=2021-08-18, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2021439e7e, moduleTitle=Eur Arch Otorhinolaryngol：顺铂化疗对内耳功能和血清prestin浓度的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2021439e7e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737729, encodeId=57781e3772998, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, objectType=article, longId=217452, objectId=1a0421e45297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0421e45297, replyNumber=0, likeNumber=88, createdTime=2021-10-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0421e45297, moduleTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0421e45297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737686, encodeId=87181e376868d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：二次减瘤术对于铂敏感的复发性卵巢癌到底有无益处？, objectType=article, longId=208242, objectId=c6c320824279, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6c320824279, replyNumber=0, likeNumber=68, createdTime=2022-02-03, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6c320824279, moduleTitle=Lancet oncol：二次减瘤术对于铂敏感的复发性卵巢癌到底有无益处？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6c320824279)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737698, encodeId=8cf11e3769825, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, objectType=article, longId=211980, objectId=f93f211980ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93f211980ae, replyNumber=0, likeNumber=79, createdTime=2021-10-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93f211980ae, moduleTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93f211980ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737725, encodeId=7f561e3772566, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, objectType=article, longId=216311, objectId=0e3021631188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3021631188, replyNumber=0, likeNumber=64, createdTime=2022-02-26, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3021631188, moduleTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3021631188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737761, encodeId=5f521e37761dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=293025, objectId=724d293025d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724d293025d7, replyNumber=0, likeNumber=57, createdTime=2022-09-28, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724d293025d7, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724d293025d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737695, encodeId=0cbd1e37695eb, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, objectType=article, longId=211375, objectId=15302113e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15302113e548, replyNumber=0, likeNumber=79, createdTime=2021-07-03, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15302113e548, moduleTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15302113e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737749, encodeId=c3791e377492b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=切除修复交叉互补基因1与铂类药物耐药, objectType=article, longId=221041, objectId=4de4221041c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4de4221041c2, replyNumber=0, likeNumber=76, createdTime=2022-09-06, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4de4221041c2, moduleTitle=切除修复交叉互补基因1与铂类药物耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4de4221041c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法

2022-03-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效

2022-10-25

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA

2022-05-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2022-06-20

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2022-03-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期

2021-11-09

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性

2021-12-23

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Eur J Cancer：采用顺铂或表柔比星进行动脉化疗栓塞治疗肝癌的疗效

2022-08-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2021-12-18

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Nat Med：Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究

2022-06-30

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2022-01-07

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果

2021-12-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Eur Arch Otorhinolaryngol：顺铂化疗对内耳功能和血清prestin浓度的影响

2021-08-18

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性

2021-10-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：二次减瘤术对于铂敏感的复发性卵巢癌到底有无益处？

2022-02-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？

2021-10-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果

2022-02-26

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-09-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌

2021-07-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

切除修复交叉互补基因1与铂类药物耐药

2022-09-06

科室
- - 订阅+
  - 更多科室
工具
服务